Study S000693

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02194595
Acronym: PREVAIL
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 105
Start: 2014-09
Primary completion: 2021-12
Lead sponsor: Mount Sinai Hospital, Canada
Conditions: Type 2 Diabetes
Interventions: DRUG:Basal insulin and exenatide; DRUG:Basal insulin only; DRUG:Basal insulin and bolus insulin
Results posted: FALSE

Registered primary outcomes

Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2) [8 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009210	The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes. Retnakaran R, Cardiovascular diabetology	2023	Randomized trial	PMID 36894921 DOI	cites ClinicalTrials.gov:NCT02194595; registry reference DERIVED:36894921